Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters

Journal of Clinical Oncology

Volumn 34, Issue 34, 2016, Pages 4151-4160

  Von Bueren, André O ^a,b   Kortmann, Rolf Dieter ^c   Von Hoff, Katja ^a,e   Friedrich, Carsten ^a,d   Mynarek, Martin ^a   Müller, Klaus ^c   Goschzik, Tobias ^f   Zur Mühlen, Anja ^f   Gerber, Nicolas ^e,l   Warmuth Metz, Monika ^e   Soerensen, Niels ^e   Deinlein, Frank ^e   Benesch, Martin ^m   Zwiener, Isabella ^g   Kwiecien, Robert ^h   Faldum, Andreas ^g,h   Bode, Udo ^f   Fleischhack, Gudrun ⁱ   Hovestadt, Volker ^j   Kool, Marcel ^j   Jones, David ^j   Northcott, Paul ^j,n   Kuehl, Joachim ^e   Pfister, Stefan ^j,k   Pietsch, Torsten ^f   Rutkowski, Stefan ^a   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^l UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^m MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁿ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; METHOTREXATE; MYC PROTEIN; PROTEIN P53; SONIC HEDGEHOG PROTEIN; TEMOZOLOMIDE; WNT PROTEIN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHILD; CHROMOSOME 11; CHROMOSOME LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIOSPINAL IRRADIATION; EVENT FREE SURVIVAL; EXON; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; INTERMEDIATE RISK PATIENT; LEUKOENCEPHALOPATHY; LOW RISK PATIENT; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; METASTATIC MEDULLOBLASTOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT; WNT SIGNALING PATHWAY; AUSTRIA; CEREBELLAR NEOPLASMS; CLINICAL TRIAL; GERMANY; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; PROGNOSIS; RISK FACTOR; SKULL IRRADIATION; SWITZERLAND; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRIA; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; GERMANY; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MEDULLOBLASTOMA; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; SWITZERLAND; YOUNG ADULT;

EID: 84995893090     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.2428     Document Type: Article

References (31)

1. Taylor MD, Northcott PA, Korshunov A, et al: Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 123:465-472, 2012
2. Packer RJ, Rood BR, MacDonald TJ: Medulloblastoma: Present concepts of stratification into risk groups. Pediatr Neurosurg 39:60-67, 2003
3. Kortmann RD, Kühl J, Timmermann B, et al: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46:269-279, 2000
4. von Hoff K, Hinkes B, Gerber NU, et al: Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 45:1209-1217, 2009
5. Taylor RE, Bailey CC, Robinson KJ, et al: Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41:727-734, 2005
6. Zeltzer PM, Boyett JM, Finlay JL, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845, 1999
7. Packer RJ, Sutton LN, Elterman R, et al: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81:690-698, 1994
8. Gandola L, Massimino M, Cefalo G, et al: Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 27:566-571, 2009
9. Gajjar A, Chintagumpala M, Ashley D, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 7:813-820, 2006
10. Jakacki RI, Burger PC, Zhou T, et al: Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: A Children's Oncology Group Phase I/II study. J Clin Oncol 30:2648-2653, 2012
11. Dufour C, Kieffer V, Varlet P, et al: Tandem high-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuroectodermic tumors. Pediatr Blood Cancer 61:1398-1402, 2014
12. Rutkowski S, Bode U, Deinlein F, et al: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352:978-986, 2005
13. Allen J, Donahue B, Mehta M, et al: A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: A report from the Children's Oncology Group (CCG 9931). Int J Radiat Oncol Biol Phys 74:1006-1011, 2009
14. Lannering B, Rutkowski S, Doz F, et al: Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: Results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30:3187-3193, 2012
15. Pompe RS, von Bueren AO, Mynarek M, et al: Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. Eur J Cancer 51:2634-2642, 2015
16. Louis DN, Ohgaki H, Wiestler OD, et al: WHO Classification of Tumours of the Central Nervous System. Lyon, France, IARC Press, 2007
17. Koch A, Waha A, Tonn JC, et al: Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93:445-449, 2001
18. Gessi M, von Bueren A, Treszl A, et al: MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system. Neuro-oncol 16:924-932, 2014
19. Hovestadt V, Remke M, Kool M, et al: Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125:913-916, 2013
20. Pietsch T, Schmidt R, Remke M, et al: Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol 128:137-149, 2014
21. von Bueren AO, von Hoff K, Pietsch T, et al: Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-oncol 13:669-679, 2011
22. Warmuth-Metz M, Bison B, Leykamm S: Neuroradiologic review in pediatric brain tumor studies. Klin Neuroradiol 19:263-273, 2009
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Kool M, Korshunov A, Remke M, et al: Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123:473-484, 2012
25. Ellison DW, Onilude OE, Lindsey JC, et al: β-Catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951-7957, 2005
26. Shih DJ, Northcott PA, Remke M, et al: Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 32:886-896, 2014
27. Gilbertson RJ: Medulloblastoma: Signalling a change in treatment. Lancet Oncol 5:209-218, 2004
28. Ramaswamy V, Remke M, Bouffet E, et al: Recurrence patterns across medulloblastoma subgroups: An integrated clinical and molecular analysis. Lancet Oncol 14:1200-1207, 2013
29. Tarbell NJ, Friedman H, Polkinghorn WR, et al: High-risk medulloblastoma: A pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 31:2936-2941, 2013
30. Merchant TE, Wang M-H, Haida T, et al: Medulloblastoma: Long-term results for patients treated with definitive radiation therapy during the computed tomography era. Int J Radiat Oncol Biol Phys 36:29-35, 1996
31. Sanders RP, Onar A, Boyett JM, et al: M1 Medulloblastoma: High risk at any age. J Neurooncol 90:351-355, 2008